Gilead Sciences Statistics

Total Valuation

Gilead Sciences has a market cap or net worth of CLP 143.70 trillion. The enterprise value is 155.23 trillion.

Market Cap	143.70T
Enterprise Value	155.23T

Important Dates

The next confirmed earnings date is Thursday, May 7, 2026.

Earnings Date	May 7, 2026
Ex-Dividend Date	Mar 13, 2026

Share Statistics

Current Share Class	1.24B
Shares Outstanding	n/a
Shares Change (YoY)	n/a
Shares Change (QoQ)	-0.08%
Owned by Insiders (%)	0.10%
Owned by Institutions (%)	88.87%
Float	1.24B

Valuation Ratios

The trailing PE ratio is 18.75 and the forward PE ratio is 15.10.

PE Ratio	18.75
Forward PE	15.10
PS Ratio	5.42
PB Ratio	7.05
P/TBV Ratio	n/a
P/FCF Ratio	16.87
P/OCF Ratio	15.92
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 11.75, with an EV/FCF ratio of 18.22.

EV / Earnings	20.25
EV / Sales	5.89
EV / EBITDA	11.75
EV / EBIT	14.67
EV / FCF	18.22

Financial Position

The company has a current ratio of 1.55, with a Debt / Equity ratio of 1.13.

Current Ratio	1.55
Quick Ratio	1.23
Debt / Equity	1.13
Debt / EBITDA	1.73
Debt / FCF	2.70
Interest Coverage	11.54

Financial Efficiency

Return on equity (ROE) is 40.66% and return on invested capital (ROIC) is 26.86%.

Return on Equity (ROE)	40.66%
Return on Assets (ROA)	12.52%
Return on Invested Capital (ROIC)	26.86%
Return on Capital Employed (ROCE)	25.03%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	1.56B
Profits Per Employee	450.91M
Employee Count	17,000
Asset Turnover	0.50
Inventory Turnover	3.58

Taxes

In the past 12 months, Gilead Sciences has paid 1.16 trillion in taxes.

Income Tax	1.16T
Effective Tax Rate	13.13%

Stock Price Statistics

The stock price has increased by +23.10% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+23.10%
50-Day Moving Average	110.43
200-Day Moving Average	110.43
Relative Strength Index (RSI)	100.00
Average Volume (20 Days)	n/a

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	3.46

Income Statement

In the last 12 months, Gilead Sciences had revenue of CLP 26.52 trillion and earned 7.67 trillion in profits. Earnings per share was 6,107.22.

Revenue	26.52T
Gross Profit	20.91T
Operating Income	10.64T
Pretax Income	8.82T
Net Income	7.67T
EBITDA	13.13T
EBIT	10.64T
Earnings Per Share (EPS)	6,107.22

Balance Sheet

The company has 8.66 trillion in cash and 23.01 trillion in debt, giving a net cash position of -11,668.57 billion.

Cash & Cash Equivalents	8.66T
Total Debt	23.01T
Net Cash	-11,668.57B
Net Cash Per Share	n/a
Equity (Book Value)	20.37T
Book Value Per Share	16,478.07
Working Capital	5.88T

Cash Flow

In the last 12 months, operating cash flow was 9.02 trillion and capital expenditures -507.13 billion, giving a free cash flow of 8.52 trillion.

Operating Cash Flow	9.02T
Capital Expenditures	-507.13B
Depreciation & Amortization	2.46T
Net Borrowing	-1,594.22B
Free Cash Flow	8.52T
FCF Per Share	n/a

Margins

Gross margin is 78.84%, with operating and profit margins of 40.14% and 28.90%.

Gross Margin	78.84%
Operating Margin	40.14%
Pretax Margin	33.27%
Profit Margin	28.90%
EBITDA Margin	49.51%
EBIT Margin	40.14%
FCF Margin	32.12%

Dividends & Yields

This stock pays an annual dividend of 2,964.91, which amounts to a dividend yield of 2,684.88%.

Dividend Per Share	2,964.91
Dividend Yield	2,684.88%
Dividend Growth (YoY)	1.41%
Years of Dividend Growth	2
Payout Ratio	47.04%
Buyback Yield	0.24%
Shareholder Yield	2,685.12%
Earnings Yield	5.33%
FCF Yield	5.93%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Gilead Sciences has an Altman Z-Score of 3.9 and a Piotroski F-Score of 7.

Altman Z-Score	3.9
Piotroski F-Score	7